ArticleMedicine and pharmacy reports2026
Urothelial carcinoma with trophoblastic differentiation: case report and review of literature.
Article in Medicine and pharmacy reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urothelial carcinoma with trophoblastic differentiation (UCTD) is a rare histological variant of urothelial carcinoma characterized by the presence of trophoblastic elements and expression of β-human chorionic gonadotropin (β-hCG). Published evidence is limited, and the clinical behavior of this variant remains incompletely understood. The objective of this study is to review the available literature regarding the incidence, clinicopathological characteristics, treatment modalities, recurrence patterns, survival outcomes, and prognostic implications and to present the case of a patient with UCTD. A 66-year-old male patient presented in February 2025 with a 2-month history of progressive left inguinal swelling and recurrent left hydrocele. Past medical history revealed: radical cystectomy with ileal neobladder, pelvic lymphadenectomy (for bladder pT2G3 recurrent BCG resistant bladder tumor) performed on the 28th of June 2018. Full body contrast CT scan had been performed on the 24th of December 2024 and revealed a left inguinal adenopathy conglomerate 9.93 cm in length, with the largest lymph node measuring 2.5 cm, bilateral peritesticular fluid collections (hydrocele) with no evidence of local tumor recurrence in the neobladder or prostate bed and a supradiaphragmatic, calcified pleural mass (3.4 × 1.8 cm). Scrotal ultrasound revealed: large bilateral hydrocele, left epididymal and upper testicular pole tumor (~2 cm in size) with increased Doppler vascularity and a large left inguinal adenopathy conglomerate (~10 cm in size) with increased Doppler vascularity. Testicular cancer serum markers were performed and a serum β-hCG of 5893 mIU/ml, was found. Ultrasonographical assessment and positive testicular cancer biomarkers prompted us to suspect a testicular tumor with inguinal lymph node metastases. Patient was referred for surgery. Left inguinal radical orchidectomy was performed along with left inguinal lymphadenectomy. Histopathological examination of the testicle revealed testicular and epididymal inflammation. Lymph node examination revealed urothelial carcinoma with squamous and trophoblastic differentiation, PDL1(22C3) positive, CK7 positive, GATA3 positive, CK20 positive, p16 negative and beta HCG positive on 10% of cells. Patient was started on platinum-based chemotherapy with rapid disease progression and died of metastatic complications approximately 11 months after the initial recurrence signs were visible on the CT scan. Conclusions: UCTD is a rare and aggressive variant of urothelial carcinoma associated with unfavorable oncological outcomes. Available evidence supports aggressive treatment and prolonged follow-up. To our knowledge, this may represent one of the few reported, very late recurrences after radical cystectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.